DBV Technologies SA (DBV) EUR0.10
€0.01
(1.72%)
- Add to watchlist
- This stock can be held in a
€0.01
(1.72%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
€0.01
(1.72%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Business summary
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.
Contact details
Important dates
General stock information
- Short code:
- DBV
- ISIN:
- FR0010417345
- Market cap:
- €59.59 million
- Shares in issue:
- 96.27 million
- Sector:
- Biotechnology
- Exchange:
- Euronext Paris
- Country:
- France
- Currency:
- Euro
- Indices:
- n/a
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.